Advertisement

Volume 3, Issue 9

 

Cover Image

Cover Figure: Definitive involved-site radiation therapy administered for stage IA nodular lymphocyte-predominant Hodgkin lymphoma of the right side of the neck.
See the article by Pinnix et al.

WASHINGTON, D.C., May 14, 2019 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

 

The treatment of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma has been an area of debate. In the study by Pinnix and colleagues, the use of involved-site radiation therapy appeared to be as effective as larger radiation fields, although a longer follow-up is necessary to confirm these excellent results.

 

 

The introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib revolutionized the treatment of chronic lymphocytic leukemia. However, some patients do not benefit from it because of inefficacy or intolerable side effects. Acalabrutinib is a covalent BTK inhibitor with greater selectivity than ibrutinib. Byrd and colleagues explored acalabrutinib in patients refractory to or intolerant of ibrutinib, finding exciting evidence for efficacy and tolerability.

 

 

Patients with sickle cell disease (SCD) have frequent pain crises and are also at risk for osteonecrosis. Adesina and colleagues explored the impact of bone mineral density on these events and found a high prevalence of low mineral bone density in children with SCD that was independent of height. Those individuals with low bone density were more likely to have chronic pain and develop hip osteonecrosis, which highlights the importance of this finding.

 

 

Patients with hemophilia lack factor VIII. However, the development of inhibitors can be a daunting clinical challenge. Factor VIII is known to be ectopically expressed in megakaryocytes and stored in α-granules. Poncz and colleagues explore the interesting approach of infusing megakaryocytes derived from induced-pluripotent stem cells or platelets expressing factor VIII in murine models, demonstrating their potential therapeutic use.

 

 

Patients with immune thrombotic thrombocytopenia purpura are often treated with rituximab. Despite the effectiveness of this treatment, a significant proportion of patients relapse. Sun and colleagues explored the predictors of relapse and make important findings that may help guide future treatments and prognosis.

 

 

A number of studies have explored the use of rabbit antithymocyte globulin (ATG) in the setting of allogeneic hematopoietic cell transplantation with differing results. Storek and colleagues explored the pharmacokinetics of ATG exposure before and after transplantation with interesting and provocative findings that may help explain some of the discrepancies found.

 

 


Featured Visual Abstract

Structural basis of the leukocyte integrin Mac-1 I-domain interactions with the platelet glycoprotein Ib

Juliet Morgan, Muhammad Saleem, Ruiqi Ng, Caroline Armstrong, Szu S. Wong, Simon G. Caulton, Alice Fickling, Huw E. L. Williams, Adam D. Munday, José A. López, Mark S. Searle and Jonas Emsley

 

 

 

 

 

 

 

 

Blood Advances is the open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.